AP
IDYA icon

Antipodes Partners’s IDEAYA Biosciences IDYA Stock Holding History

Antipodes Partners’s Portfolio IDYA Stock Details IDYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-917
Closed -$30.6K – 139
2026
Q1 		$30.6K Sell
917
-233
-20% -$7.82K ﹤0.01% 113
2025
Q4 		$39.8K Buy
1,150
+380
+49% +$12.1K ﹤0.01% 111
2025
Q3 		$21K Buy
+770
New +$18.6K ﹤0.01% 111

Other funds holding IDYA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Antipodes Partners's IDYA Position: Q2 2026 in Review

Antipodes Partners sold out of IDEAYA Biosciences (IDYA) in Q2 2026, closing a stake of 917 shares — an estimated $30.6K sold.

Antipodes Partners first reported a position in IDYA in Q3 2025 and held it in 3 quarters. The position peaked at $39.8K in Q4 2025. 285 funds tracked by Wall St. Rank hold IDYA as of Q2 2026.

  • Antipodes Partners reported no remaining IDEAYA Biosciences position as of Q2 2026 after selling out during the quarter.
  • Antipodes Partners sold 917 IDEAYA Biosciences shares in Q2 2026, an estimated $30.6K.
  • Antipodes Partners first reported a position in IDEAYA Biosciences in Q3 2025 and held it in 3 quarters.
  • Antipodes Partners's IDEAYA Biosciences position peaked at $39.8K in Q4 2025.
  • 285 funds tracked by Wall St. Rank held IDEAYA Biosciences as of Q2 2026.

Based on Antipodes Partners's 13F filing for Q2 2026, filed 6 Aug 2026.